Genomic Profiling of Pancreatic Cystic Tumors

Status Not yet recruiting

Clinical Trial Summary

This study aims to find out whether quantitative and qualitative analysis, including genetic mutation analysis, of samples obtained from patients with pancreatic cysts is associated with the risk of malignancy, and helpful in the differential diagnosis of mucinous and serous cysts. The study design is a single-arm prospective cohort observational study. Using blood, pancreatic cyst fluid, and pancreatic cyst tissue, genetic mutation analysis and measurement of various biomarkers are performed, and the relationship between these and malignancy or whether they are helpful in distinguishing mucinous and serous cysts is analyzed. The primary outcome is genetic variants of pancreatic cysts associated with malignancy. The secondary outcomes are factors including genetic variants that differentiate mucinous from serous cysts.

Clinical Trial Description

Pancreatic cysts, especially mucinous cysts, are precancerous lesions that can cause pancreatic cancer, and follow-up surveillance is important. However, there is a lack of clear medical evidence for the proper method and timing of follow-up, so the current follow-up strategies rely heavily on the opinions of experts. Although mucinous pancreatic cyst is known as a precancerous lesion, the incidence of cancer is about 1-5%. Therefore, if the risk of malignant disease can be more accurately predicted in patients with pancreatic cysts, patients with a high risk of malignant disease can be more intensively monitored and improved survival rates can be expected through early detection of pancreatic cancer. In addition, unnecessary medical resource consumption can be reduced by increasing the follow-up interval of pancreatic cyst patients with low risk of malignancy or not following them at all. To this end, in addition to imaging characteristics of pancreatic cysts, which are currently suggested as risk factors for malignancy in most guidelines for pancreatic cysts, differential diagnosis of pancreatic cysts based on new biomarkers such as genetic mutations and malignant risk assessment are necessary. Therefore, in this study, the investigators comprehensively analyze the blood, pancreatic cyst fluid, and pancreatic cyst tissue of patients with pancreatic cysts to explore biomarkers including genetic mutations that are helpful in the differential diagnosis of pancreatic cyst and the diagnosis of malignant tumors. ;

Study Design

Related Conditions & MeSH terms

Pancreatic Cyst

Clinical Trial Details

NCT number	NCT06195904
Study type	Observational
Source	Samsung Medical Center
Contact	Young Hoon Choi, MD, PhD
Phone	82-2-2258-6020
Email	crzyzs@naver.com
Status	Not yet recruiting
Phase
Start date	January 15, 2024
Completion date	May 15, 2030

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05572788` - Rectal Indomethacin to Prevent Acute Pancreatitis in EUS-FNA of Pancreatic Cysts	N/A
Completed	`NCT01770405` - Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract	N/A
Completed	`NCT01643460` - Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts	N/A
Recruiting	`NCT03260842` - Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer
Recruiting	`NCT04291651` - UCSF PANC Cyst Registry
Recruiting	`NCT05692596` - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Recruiting	`NCT03334708` - A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Recruiting	`NCT04140435` - EUS-guided Through-the-needle Microforceps Biopsy Outcomes
Terminated	`NCT00550108` - Management of Incidentally Discovered Pancreatic Cysts	Phase 3
Recruiting	`NCT03492151` - Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
Completed	`NCT03169842` - Cyst Fluid Glucose for On-site Diagnosis of Mucinous Pancreatic Cysts	N/A
Not yet recruiting	`NCT06320990` - Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection	Phase 1
Recruiting	`NCT04404101` - Evaluation of Pancreatic Cystic Lesions Via EUS-guided Fine Needle Aspiration With and Without Micro Forceps Biopsies	N/A
Recruiting	`NCT06305728` - A Study of Early Cancer Detection in People at High Risk of Developing Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting	`NCT06340620` - EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope	N/A
Recruiting	`NCT02343692` - A Phase II Multicentre Trial of Endoscopic Ultrasound Guided Radiofrequency Ablation of Cystic Tumours of the Pancreas	N/A
Recruiting	`NCT02775461` - Pancreas Registry and High Risk Registry
Active, not recruiting	`NCT01563133` - Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas	N/A
Completed	`NCT00222898` - Cancer Detection in Pancreatic Cysts	N/A
Completed	`NCT03740360` - Contrast Enhanced Ultrasound and Molecular Analysis in the Diagnosis of Pancreatic Cyst

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.